BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 35095286)

  • 1. Effectiveness and Safety of Anlotinib Monotherapy for Patients with Extensive-stage Small-Cell Lung Cancer Who Progressed to Chemotherapy: A Real-world Exploratory Study.
    Li Y; Sun Z; Sun W; Wang H; Zu J
    Clin Med Insights Oncol; 2022; 16():11795549211067184. PubMed ID: 35095286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Anlotinib Monotherapy as Third-Line Therapy for Elderly Patients with Non-Small Cell Lung Cancer: A Real-World Exploratory Study.
    Jiang HT; Li W; Zhang B; Gong Q; Qie HL
    Int J Gen Med; 2021; 14():7625-7637. PubMed ID: 34754233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Anlotinib for Elderly Patients with Previously Treated Extensive-Stage SCLC and the Prognostic Significance of Common Adverse Reactions.
    Song PF; Xu N; Li Q
    Cancer Manag Res; 2020; 12():11133-11143. PubMed ID: 33173346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Efficacy and Safety of Anlotinib in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study.
    Zheng HR; Jiang AM; Gao H; Liu N; Zheng XQ; Fu X; Zhang R; Ruan ZP; Tian T; Liang X; Yao Y
    Cancer Manag Res; 2022; 14():2273-2287. PubMed ID: 35942069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study.
    Zheng HR; Jiang AM; Gao H; Liu N; Zheng XQ; Fu X; Ruan ZP; Tian T; Liang X; Yao Y
    Front Oncol; 2022; 12():894835. PubMed ID: 36203439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility and Safety of Anlotinib Monotherapy for Patients with Previously Treated Advanced Esophageal Squamous Cell Carcinoma: A Real-World Exploratory Study.
    Zhang S; Wang X; Gu H; Liu JQ
    Cancer Manag Res; 2022; 14():1715-1727. PubMed ID: 35592110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Activity and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Previously Treated Small Cell Lung Cancer.
    Hao YY; Qiao YP; Cheng JD
    Int J Gen Med; 2021; 14():10483-10493. PubMed ID: 35002304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study.
    Kong T; Chen L; Zhao X; Duan F; Zhou H; Wang L; Liu D
    Invest New Drugs; 2022 Oct; 40(5):1095-1105. PubMed ID: 35788937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer.
    Gao X; Peng L; Zhang L; Huang K; Yi C; Li B; Meng X; Li J
    J Cancer Res Clin Oncol; 2022 Oct; 148(10):2661-2671. PubMed ID: 34748028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretreatment prognostic nutritional index is a prognostic marker for extensive-stage small cell lung cancer patients treated with anlotinib.
    Liu J; Li S; Zhang S; Yang C; Zhang L; Zhang B; Cheng Y; Wang C
    J Thorac Dis; 2020 Oct; 12(10):5765-5773. PubMed ID: 33209408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of VEGFR2 gene polymorphism on the clinical outcomes of apatinib for patients with chemotherapy-refractory extensive-stage SCLC: a real-world retrospective study.
    Geng N; Ding CM; Liu ZK; Song S; Hu WX
    Int J Clin Oncol; 2021 Apr; 26(4):670-683. PubMed ID: 33392882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic effectiveness of anlotinib combined with etoposide in extensive-stage small-cell lung cancer: a single-arm, phase II trial.
    Wu Y; Zhou X; Zhao W; Wang Q; Han Z; Wang L; Zhou W; Zhou T; Song H; Chen Y; Yang K; Shi L; Pan B; Guo R; Zhou G; Jiang F; Feng J; Shen B
    Invest New Drugs; 2023 Dec; 41(6):825-833. PubMed ID: 37837490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to first-line treatment predicts progression-free survival benefit of small-cell lung cancer patients treated with anlotinib.
    Qin B; Xin L; Hou Q; Yang B; Zhang J; Qi X; Wei Y; Hu Y; Xiong Q
    Cancer Med; 2021 Jun; 10(12):3896-3904. PubMed ID: 33960145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Study.
    Zhong Q; Liu Z
    Cancer Manag Res; 2021; 13():4115-4128. PubMed ID: 34045898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Anlotinib for Patients with Advanced NSCLC Who Progressed After Standard Regimens and the Preliminary Analysis of an Efficacy Predictor.
    Cheng JD; Chai LX; Zhao ZP; Hao YY; Li S
    Cancer Manag Res; 2020; 12():5641-5650. PubMed ID: 32765067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implication of
    Li X; Cheng Y; Zhu B; Geng M; Yan P; Hu M
    Technol Cancer Res Treat; 2022; 21():15330338221080993. PubMed ID: 35443836
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study.
    Chen Q; Li Y; Zhang W; Wang C; Yang S; Guo Q
    J Cancer Res Clin Oncol; 2022 Feb; 148(2):401-408. PubMed ID: 34797416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of anlotinib as maintenance therapy after induction chemotherapy in extensive-stage small-cell lung cancer.
    Wang N; Zhao L; Zhang D; Kong F
    Anticancer Drugs; 2023 Apr; 34(4):558-562. PubMed ID: 36728981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Gefitinib Plus Anlotinib for Patients with EGFR Positive Advanced Non-Small-Cell Lung Cancer: A Retrospective Exploratory Study.
    Hu WX; Peng JC; Wang Y; Jin H; Geng N
    Int J Gen Med; 2022; 15():4453-4464. PubMed ID: 35509604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of apatinib as second or later-line therapy in extensive-stage small cell lung cancer: a prospective, exploratory, single-arm, multi-center clinical trial.
    Liu Q; Xu JY; Xu YH; Chen M; Deng LC; Wu JP; Zhou T; Zhang LQ; Tan J; Pu XX; Shang YL; Hua J; Li YQ; Cai W; Gu YL; Peng XC; Chan PC; Jabbour SK; Nam HS; Hua D
    Transl Lung Cancer Res; 2022 May; 11(5):832-844. PubMed ID: 35693282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.